Efficacy and Safety of Modified Qingjin Huatantang Combined with Western Medicine in Treatment of Phlegm-heat： A Systematic Review and Meta-analysis
10.13422/j.cnki.syfjx.20241992
- VernacularTitle:经典名方清金化痰汤加减联合西医治疗痰热证患者有效性与安全性的系统评价和Meta分析
- Author:
Lu WANG
1
;
Jiajia WANG
1
;
Jiamin LIU
1
;
Jiansheng LI
1
Author Information
1. Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province and Education Ministry of P.R. China/Henan Key Laboratory of Chinese Medicine for Respiratory Disease，Henan University of Chinese Medicine，Zhengzhou 450046，China
- Publication Type:Journal Article
- Keywords:
Qingjin Huatantang;
phlegm-heat syndrome;
randomized controlled trials;
Meta-analysis
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(19):154-162
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the efficacy and safety of modified Qingjin Huatantang combined with Western medicine in the treatment of phlegm-heat and to provide reference for the clinical application of this therapy and development of new drugs. MethodChina Biology Medicine （CBM），Chinan National Knowledge Infrastructure （CNKI），Wanfang Data，VIP，and PubMed were searched for the randomized controlled trials （RCTs） of modified Qingjin Huatantang in the treatment of phlegm-heat that were published from inception to November 1，2023. Two researchers independently screened the RCTs and extracted data according to pre-set inclusion and exclusion criteria. The Cochrane Collaboration's tool for assessing risk of bias was used for quality evaluation. Revman 5.4 was used for the Meta-analysis of outcome indicators. ResultA total of 91 RCTs were included，involving 7 868 patients （3 942 patients in the experimental group and 3 926 patients in the control group）. The results of Meta-analysis showed that compared with simple Western medicine treatment，modified Qingjin Huatantang combined with Western medicine improved the clinical response rate ［relative risk （RR）=1.16，95% confidence interval （CI）［1.14，1.19］，P<0.000 01］ and PaO2 ［mean difference （MD）=4.65，95%CI ［1.88，7.43］，P=0.001］. The combined therapy had advantages in decreasing the scores of clinical symptoms including cough ［MD=-0.69，95%CI ［-1.33，-0.06］，P=0.03），expectoration ［MD=-1.04，95%CI ［-2.02，-0.07］，P=0.04），phlegm volume ［MD=-0.38，95%CI ［-0.69，-0.07］，P=0.02］，fever ［MD=-0.22，95%CI ［-0.36，-0.09］，P=0.000 8］，wheezing ［MD=-0.34，95%CI ［-0.40，-0.29］，P<0.000 01］，chest tightness ［MD=-0.32，95%CI ［-0.39，-0.26］，P<0.000 01］，and rales ［MD=-0.35，95%CI ［-0.42，-0.27］，P<0.000 01］）. Moreover，the combined therapy outperformed Western medicine treatment alone in reducing PaCO2 （MD=-5.42，95%CI ［-7.12，-3.72］，P<0.000 01］， white blood cell count （WBC） ［MD=-1.27，95%CI ［-1.56，-0.97］，P<0.000 01］，C-reactive protein （CRP） ［standard mean difference （SMD）=-1.52，95%CI ［-1.96，-1.07］，P<0.000 01］， procalcitonin （PCT） ［SMD=-1.23，95%CI ［-1.87，-0.58］，P=0.000 2］，and tumor necrosis factor （TNF）-α ［SMD=-2.63，95%CI ［-3.19，-2.08］，P<0.000 01］）， shortening hospital stay ［MD=-2.45，95%CI ［-3.34，-1.57］，P<0.000 01］， and lowering the incidence of adverse reactions ［RR=0.66，95%CI （0.49，0.88），P=0.005］. ConclusionModified Qingjin Huatantang combined with Western medicine in the treatment of patients with phlegm-heat syndrome has advantages in improving clinical response rate and PaO2， reducing symptom scores and inflammatory factors， and shortening hospital stay， with high safety.
